Two weeks after Herceptin was licensed by regulatory authorities for use in early breast cancer, NICE has issued draft guidance recommending the drug for women with early state HER2-positive breast cancer, except where there are concerns about the woman's cardiac function.
Two weeks after Herceptin was licensed by regulatory authorities for use in early breast cancer, the UK's National Institute for Clinical Excellence (NICE) has issued draft guidance recommending the drug for women with early stage HER2-positive breast cancer, except where there are concerns about the woman's cardiac function.
Once final guidance is published in July, there will be a 3-month grace period for its implementation and anyone failing to offer Herceptin to eligible patients may face legal proceedings. NICE chief executive Andrew Dillon said that the treatment is clinically- and cost-effective in the early stage of the disease.
Herceptin (trastuzumab) is a monoclonal antibody that targets breast cancer cells. According to Cancer Research UK, 15–25% of breast cancer patients are likely to respond to treatment with Herceptin. The treatment blocks the cancer cells' ability to grow, and increases the effect of chemotherapy drugs on breast cancer cells.
More than 5000 women in the UK are eligible for treatment by Herceptin. However, at an estimated £100 million a year, the UK National Health Service (NHS) Confederation has warned that cutbacks elsewhere may be necessary.
www.nice.org.uk
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.